Home / Health / Experts Warn of Serious Side Effects
Experts Warn of Serious Side Effects
12 Aug
Summary
- Drug Vykat XR faces safety concerns from experts.
- Seven deaths reported to FDA as of July 31, 2026.
- Organizations urge transparency and careful monitoring.
Safety concerns have been voiced by experts regarding Neurocrine's drug, Vykat XR, intended to treat hyperphagia in Prader-Willi syndrome. Serious adverse events have emerged since the drug became more widely available.
According to a joint statement from the Foundation for Prader-Willi Research and the International Prader-Willi Syndrome Organisation, the U.S. Food and Drug Administration's Adverse Event Monitoring System has recorded seven reports of patient deaths linked to Vykat XR as of July 31, 2026.
These organizations highlighted the concerning nature of these reports, emphasizing the need for transparency about the drug's safety profile. They clarified that these reports do not confirm a direct causal relationship.
Despite the concerns, the groups stated their intention is not to discourage Vykat XR's use but to promote informed prescribing, careful patient selection, and close monitoring, especially for those with known risk factors.
